Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.72 |
| ▸ | MET | P08581 | 2/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.48 |
| ▸ | STK3 | Q13188 | 2/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.48 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.48 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797740 | 1.00 | AURKA (0.72) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3808724 | 0.92 | MET (0.75) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3805989 | 0.92 | MET (0.75) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3803695 | 0.88 | AURKA (0.64) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3803693 | 0.88 | AURKA (0.64) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL5405465 | 0.86 | MET (0.82) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3799653 | 0.83 | AURKA (1.00) | AURKAAURKBFGFR1KDRPDGFRB | |
| SCHEMBL3799652 | 0.83 | AURKA (1.00) | AURKAAURKBFGFR1KDRPDGFRB | |
| SCHEMBL3799361 | 0.83 | AURKA (0.81) | AURKAAURKBMETFGFR1KDR | |
| SCHEMBL3799365 | 0.83 | AURKA (0.81) | AURKAAURKBMETFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | claimed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | claimed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | CDK2, MAP3K19, MAP3K20 | AURKA 96/4885AURKB 69/4885MET 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.